Information for Health Professionals
Notice: The Manitoba Biosimilars Initiative was implemented effective August 1, 2024. More information on this initiative can be found here.
On This Page:
- Pharmacy Claims Submission Procedures and Audit
- Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary
- Submitting New or Updated Pharmacy Information
- Current Topics & Client Resources
- Provincial Acts and Regulations
- Contact Information
Pharmacy Claims Submission Procedures and Audit
Manitoba Health's current claim submission procedures and audit processes for community pharmacies are available below. (For all documents related to Claim Submission Procedures, the word “Manitoba” refers to “Manitoba Health.")
Notices
- Notice – COVID-19
- Drug Shortage Quantity Restrictions List (UPDATED November 15, 2024)
- Supply Restriction Update
- EDS Extension (UPDATED April 2021)
- 30 – Day Supply
- Notice – Pharmacy Software Vendor Price file
- Notice – Tiered Biologics Reimbursement Policy
- Tiered Biologics Flowsheet (UPDATED August 2024)
- Tiered Biologics Overview (UPDATED August 2024)
- Tiered Biologics by Specialty (UPDATED August 2024)
- Notice – Approved Compounds for Pain Management – January 19, 2018
Pharmacy Submission Procedure Manual
The DPIN Pharmacy Manual may be updated from time to time, as communicated directly to pharmacies. The current version includes all Claims Submission Procedures and associated lists/forms provided below.- Claims Submission Procedure – Advanced Glucose Monitors (UPDATED August 27, 2024)
- Claims Submission Procedure – Blood Glucose Test Strips (Revised November 7, 2024)
- Claims Submission Procedure – Manitoba Prescription Birth Control Program (EFFECTIVE October 1, 2024)
- FAQ – Manitoba Prescription Birth Control Program (EFFECTIVE October 1, 2024)
- Claims Submission Procedure – COVID-19 Oral Antiviral Drug Provision Paxlovid (EFFECTIVE October 24, 2024)
- Claims Submission Procedure – Uncomplicated Cystitis Assessment (EFFECTIVE March 7, 2022)
- Claims Submission Procedure – Manitoba HIV Medications Program (EFFECTIVE June 3, 2024)
- Manitoba HIV Medications Program Drug List (UPDATED November 7, 2024)
- FAQ – Manitoba HIV Medications Program (UPDATED May 30, 2024)
- Claims Submission Procedure – Insulin Pump Supplies (EFFECTIVE January 24, 2023)
- FAQ – Insulin Pump Supplies (January 2023)
- Claims Submission Procedure – Professional Fee Cap
- Claims Submission Procedure – Oral Oncology Drugs Dispensed at CancerCare Manitoba
- List of Oral Oncology Drugs Dispensed at CancerCare Manitoba (Updated April 1, 2024)
- Claims Submission Procedure – Extemporaneous Products (Compounding)
- Monitored Drugs Compound List (UPDATED March 31, 2022)
- PIN Flowsheet
- Claims Submission Procedure – Outsourced Extemporaneous Products
- Claims Submission Procedure – Special Authority Compounding
- Claims Submission Procedure – Manitoba Designated Drug Shortages
- Drug Shortage PIN List to November 15, 2024
- CSP Compounded Phenobarb Elixir – effective August 26, 2024
- Drug Shortage PIN – Nystatin Suspension 100,000 units/mL (CMPD) – effective July 15, 2024
- Drug Shortage PIN – Cholestyramine (US Label) – effective July 15, 2024
- CSP US-Labeled Carbamazepine CR 200mg and 400mg Tablet – effective July 2, 2024
- Drug Shortage PIN – Glucagon Injection Kit 1mg – effective February 2, 2024
- Drug Shortage PIN – Prazosin Capsule (US Label) – revised November 7, 2023
- Drug Shortage Compound – COTRIMOXAZOLE 40mg – 8mg per ml Oral Suspension
- Claims Submission Procedure – Dispensing Frequency
- Frequency of Dispensing List (UPDATED May 2019)
- Form – Frequent Dispensing Authorization
- Claims Submission Procedure – Claims with Cost Exceeding $9999.99
- Claims Submission Procedure – Methadone (UPDATED August 2021)
- FAQ – Methadone (UPDATED August 2021)
- Claims Submission Procedure – Pharmaceutical Distribution Rate Changes (UPDATED May 2019)
- Claims Submission Procedure – Mifegymiso
- List of Designated High-Cost Drugs for Reduced Pharmaceutical Distribution (Updated October 2, 2024)
- FAQ – Pharmacare Audit and Investigations
- Form – Reversal/Adjustment
- Template – Pharmacy Agreement
If your questions are not answered by reviewing the Claims Submission Procedures and FAQs provided here, please contact PDPInfoAudit@gov.mb.ca.
Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary
About the Manitoba Drug Benefits and Interchangeability Formularies
- Bulletin Archive
This is the archive of Manitoba Drug Benefits and Interchangeability Formulary Amendments. - Manitoba Drug Benefits Formulary
A list of drugs and other items specified as eligible benefits under the Manitoba Pharmacare drug benefit program. - Manitoba Drug Interchangeability Formulary
A list of interchangeable drugs, categories and prices specific to drugs listed on the Manitoba Drug Benefits Formulary. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
Effective date of transition from Regulation to Policy: October 18, 2021.
- Manitoba Drug Formulary Lookup
Search the Manitoba Drug Benefits Formulary by brand name, active ingredient, Drug Identification Number (DIN); or more advanced search options such as Therapeutic Classification. - Manitoba Drug Formulary Glossary of Terms
- EDS
Certain drugs are approved for coverage under the Exception Drug Status (EDS) Program when the use meets specific criteria as recommended by the Manitoba Drug Standards and Therapeutics Committee (MDSTC).
Effective October 18, 2021, "Part 3 Exception Drug Status" or "Part 3 benefits" will be referred to as "Exception Drug Status" or "EDS benefits".
Updated April 1 , 2024- EDS Application Processing Times
- Changes to Exception Drug Status (EDS) Approval Process and Expiry Dates
- Exception Drug Status (EDS) Request Form
- EDS Request Form: Ajovy/Emgality/Vyepti/Qulipta
- EDS Request Form: Dupixent for Eosinophilic Asthma
- EDS Request Form: Kerendia
- EDS Request Form: Nucala/Fasenra
- EDS Request Form: Ofev
- EDS Request Form: Personal Care Home
- EDS Request Form: Repatha/Praluent
- EDS Request Form: Vascepa
- EDS Indefinite Drug List (updated August 2024)
- pCPA
The pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial negotiations for brand name drugs in Canada to achieve greater value for publicly funded drug programs and patients. - CADTH Common Drug Review (CDR) Reports
Through the Common Drug Review (CDR) Process, CADTH conducts thorough and objective evaluations of the clinical, economic and patient evidence on drugs, and uses this evaluation to provide reimbursement recommendations and advice to Canada’s federal, provincial and territorial public drug plans.
Submitting New or Updated Pharmacy Information
- DPIN Registration Form (Revised Feb. 28, 2023)
Current Topics & Client Resources
Pharmacare
- About Pharmacare
- Deductible Instalment Payment Program for Pharmacare (DIPPP)
- FAQ – Advanced Glucose Monitors
Naloxone Kits
Drug Shortages Canada
- The website for reporting drug shortages and discontinuations in Canada.
Provincial Acts and Regulations
Provincial Acts and Regulations are available through the website of the Statutory Publications Office.
- The Prescription Drugs Cost Assistance Act
- Prescription Drugs Payment of Benefits Regulation
- Specified Drugs Regulation
This is the regulation that provides for the benefit lists of specified drugs under The Prescription Drugs Cost Assistance Act. It lists the drugs and criteria for eligibility for the Manitoba Pharmacare program.
Effective: April 20, 2017
- The Pharmaceutical Act
- Manitoba Drug Interchangeability Formulary
This regulation under The Pharmaceutical Act includes a list of interchangeable drugs, categories and prices. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
Effective: April 20, 2017
- Manitoba Drug Interchangeability Formulary
- The Personal Health Information Act (PHIA)
- PHIA - Information for Trustees
- The Personal Health Information Regulation
This regulation has no legislative sanction and the original should be consulted for purposes of interpreting and applying the law.
Contact Information
Provincial Drug Programs
Manitoba Health
300 Carlton Street
Winnipeg, Manitoba R3B 3M9
PDP Information and Audit
FAX: 204-786-8560
E-mail: PDPInfoAudit@gov.mb.ca
